GPT and metabolic dysfunction-associated steatotic liver disease: A study by Newsome et al., designed to evaluate semaglutide as a potential treatment for Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), showed a dose dependent decrease in ALT levels, with maximal reductions occurring around week 28 and remaining stable thereafter [38].